Stanford Cancer Institute Directory

Stanford Cancer Institute Profiles

Showing 171 - 180 of 458
    Professor of Biochemistry and, by courtesy, of Chemical Engineering and of Chemistry

    Bio

    The overarching goal of the Herschlag Lab is to understand the fundamental behavior of RNA and proteins and, in turn, how these behaviors determine and impact biology more broadly. We are particularly interested in questions of how enzymes work, how RNA folds, how proteins recognize RNA, and the roles of RNA/protein interactions in regulation and control, and the evolution of molecules and molecular interactions. The lab takes an interdisciplinary approach, spanning and integrating physics, chemistry and biology, and employing a wide range of techniques.
    Professor of Health Research and Policy (Health Services Research) and of Medicine (Cardiovascular Medicine)
    Professor of Medicine (Endocrinology)

    Bio

    Dr. Andrew Hoffman is a board certified endocrinologist who specializes in the treatment pituitary and other neuroendocrine diseases, including acromegaly, Cushing syndrome, prolactinomas and other pituitary tumors.
    Professor of Radiology (General Radiology) at the Stanford University Medical Center
    Professor of Otolaryngology - Head and Neck Surgery at the Stanford University Medical Center

    Bio

    Dr. Holsinger is Professor and Chief of Head and Neck Surgery at Stanford University. His research focuses on surgical innovation and clinical trials through NCI-funded cooperative groups. He serves as surgical principal investigator for RTOG920 and coordinated surgeon-credentialing for ECOG 3311, a prospective clinical trial to study robotic head and neck surgery. He leads an investigative device exemption trial to evaluate the safety and efficacy of anext-generation flexible robotic surgical system. In 2014, he began a prospective clinical trial to evaluate multispectral imaging of patients with oropharyngeal cancer, in an effort to discern tumor from tumor. Currently, he leads a study to evaluate hyper-spectral imaging to improve surgical vision. From 2003-2013, Dr. Holsinger worked at the Department of Head and Neck Surgery at the University of Texas M.D. Anderson Cancer Center where he founded and led the Program in Minimally Invasive and Endoscopic Head and Neck Surgery and co-directed the program in Minimally Invasive Technology in Oncologic Surgery. Dr. Holsinger’s surgical practice focuses on the surgical management of benign and malignant diseases of the thyroid, as well as head and neck cancer. His areas of research interest include endoscopic head and neck surgery, including transoral robotic surgery and transoral laser microsurgery, as well as time-honoured approaches of conservation laryngeal surgery and supracricoid partial laryngectomy. At the Cancer Center, Dr. Holsinger has led an effort to improve the quality of multidisciplinary tumor boards in H&N, but also across the Cancer Center, beginning with the founding of the H&N Multidisciplinary Cancer Care Clinical Program in 2014. Dr. Holsinger received his medical degree from Vanderbilt School of Medicine, completed his internship and residency at Baylor College of Medicine and his Fellowship in head and neck surgical oncology at The University of Texas M. D. Anderson Cancer Center. In 2003, he was awarded Fulbright Scholarship to study surgery at the University of Paris with Professor Ollivier Laccourreye and with Professor Wolfgang Steiner at the Georg-August University in Göttingen. Dr. Holsinger has authored or co-authored numerous articles and abstracts, which have appeared in publications such as the New England Journal of Medicine, Journal of the American College of Surgeons, the Journal of Clinical Oncology, Clinical Cancer Research, Head & Neck, Laryngoscope, and the Archives of Otolaryngology—Head and Neck Surgery. Board-certified by the American Board of Otolaryngology, Dr. Holsinger is a member of numerous societies including the American College of Surgeons, the American Society of Clinical Oncology, and the American Head and Neck Society.
    Henry S. Kaplan-Harry Lebeson Professor of Cancer Biology
    Associate Professor of Radiation Oncology (Radiation Therapy) at the Stanford University Medical Center
    Associate Professor of Radiation Oncology (Radiation Physics) at the Stanford University Medical Center
    Professor (Research) of Medicine (Stanford Prevention Research Center/Cancer Institute) and, by courtesy, of Health Research and Policy (Epidemiology)

    Bio

    Dr. Hsing is a professor of medicine at Stanford University and a co-leader of the Population Sciences Program at Stanford Cancer Institute. A senior fellow for the Center for Innovation in Global Health at Stanford University, Dr. Hsing has conducted population-based epidemiological studies on four continents, including North and South America, Asia, Africa, and Europe. She is a leading expert in the epidemiology and etiology of prostate, hepatobiliary, and thyroid cancers as well as in hormonal carcinogenesis and circadian rhythm. Throughout her 22-year tenure at National Cancer Institute, Dr. Hsing developed extensive expertise in molecular epidemiology, global oncology, cancer prevention, and population-based studies in international settings. She has served on numerous committees and advisory boards, most recently as a member of the Editorial Board of Cancer Epidemiology, Biomarkers & Prevention and as an academic editor of PLOS ONE. She also has served as an adjunct professor in the Department of Epidemiology and the Department of Urology at the George Washington University in Washington, D.C., as well as in the Department of Public Health of Fu Jen Catholic University’s School of Medicine in Taiwan. Dr. Hsing has authored more than 270 peer-reviewed articles, written seven book chapters, and mentored over 50 post-doctoral fellows and scholars. Dr. Hsing currently serves as PI on the following funded projects: • A pilot study to assess the feasibility of building a population-based cancer registry in Accra, Ghana; • A study to assess patterns and trends of liver cancer in the Greater Bay area and in California and to project liver cancer burden in 20 years; • A pilot study in the Bay area to investigate non-viral factors of liver cancer; • A pilot study to investigate the clinical utility of ctNDA in post-treatment surveillance of liver cancer in Mongolia; • A whole genome sequencing study of aggressive thyroid cancer to identify novel prognostic factors; • A cohort study of 10,000 healthy individuals in Taiwan to investigate social and biochemical determinants of wellness (WELL Taiwan); • A cohort study of 10,000 healthy individuals in China to investigate social and biochemical determinants of wellness (WELL China); • A multiethnic cohort study of 550,000 individuals in Singapore to investigate social and biochemical determinants of wellness (WELL Singapore) She also serves as the Stanford PI of a consortium study of a genome-wide association study (GWAS) of prostate cancer in the African countries of Ghana, Senegal, Nigeria, and South Africa. More recently, her her work involves big data studies using such resources as the National Health Insurance Research Database, SEER-Medicare, and other large administrative claims and medical record databases to identify clinically relevant questions to help inform clinical practice.
    Postdoctoral Research Fellow, Stanford Cancer Center

Affiliations

Organizations